Chemours (NYSE: CC) reported Q3 EPS of $1.27, $0.26 better than the analyst estimate of $1.01. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.59 billion.

Outlook:

Newman commented, "On the back of the strong performance in Q3, we are raising our expectations for the full year. Our new guidance reflects our expectation for strong Q4 demand, inclusive of typical seasonal patterns and against a backdrop of ongoing logistics and supply chain challenges. We expect 2021 Adjusted EBITDA within a range of $1,300 million to $1,340 million and Free Cash Flow of greater than $500 million. Longer term, our earnings and cash flow will reflect the ever-increasing value we are delivering for our customers through our unique product offering and industry leading reliability."

For earnings history and earnings-related data on Chemours (CC) click here.